Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this first in man study is to examine the safety of an experimental gene
transfer agent, RetinoStat, designed to treat neovascular age-related macular degeneration.